Journey MedicalDERM +2.39%63 FCF Margin % is 18.23% as of Mar. 2026. GuruFocus rates DERM with a GF Score™ of 63/100 and a GF Value™ of $4.17 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 958 Drug Manufacturers companies, Journey Medical ranks worse than 74.43% on this metric.
The historical rank and industry rank for Journey Medical's FCF Margin % or its related term are showing as below:
DERM'
s FCF Margin % Range Over the Past 10 Years
Min: -45.52 Med: -19.29 Max: 18.95
Current: -10.36
During the past 7 years, the highest FCF Margin % of Journey Medical was 18.95%. The lowest was -45.52%. And the median was -19.29%.
DERM's FCF Margin % is ranked worse than 74.43% of 958
companies
in the Drug Manufacturers industry
Industry Median: 2.51
vs DERM: -10.36
Journey Medical FCF Margin % Related Terms
Journey Medical FCF Margin % Historical Data
* Premium members only.
The historical data trend for Journey Medical's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Journey Medical's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Journey Medical FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Journey Medical's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Journey Medical's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Journey Medical (DERM) has a FCF Margin % of 18.23% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Journey Medical and its competitors. According to the industry distribution chart, Journey Medical ranks #713 out of 958 companies in the Drug Manufacturers industry, placing it in the top 74.4%.
Is Journey Medical's FCF Margin % too high?
Journey Medical's current FCF Margin % is 18.23%. The Drug Manufacturers industry median FCF Margin % is 2.51. Journey Medical's value of 18.23% is 626.3% above this industry median. Based on the distribution chart, Journey Medical ranks #713 out of 958 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Journey Medical has a GF Score™ of 63/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Journey Medical's FCF Margin % compare to LFCR and ANIK?
According to the Drug Manufacturers industry distribution chart, Journey Medical ranks #713 out of 958 companies for FCF Margin %. This places Journey Medical in the lower half of its industry. The industry median FCF Margin % is 2.51. Journey Medical's value of 18.23% is 626.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.51, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Journey Medical's current FCF Margin % of 18.23% is 626.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Journey Medical and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Journey Medical's current FCF Margin % is 18.23%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Journey Medical stock overvalued right now?
Based on GuruFocus' analysis, Journey Medical (DERM) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.17, compared to a current price of $6.85 — trading 64.3% above its estimated fair value. The current FCF Margin % is 18.23% and 626.3% above the Drug Manufacturers industry median of 2.51. Journey Medical's overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Journey Medical (DERM), the current FCF Margin % is 18.23% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Journey Medical (DERM) Overvalued in 2026?
Based on GuruFocus' analysis, Journey Medical stock appears to be overvalued.
The current stock price of $6.85 is trading 64.3% above its estimated GF Value™ of $4.17.
GuruFocus considers Journey Medical to be Significantly Overvalued.
Key valuation signals for DERM:
FCF Margin %: 18.23%
GF Value™: $4.17 vs. price of $6.85 (64.3% above fair value)
Industry Position: 626.3% above the Drug Manufacturers median (#713 of 958)
No single metric tells the full story. See the DERM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.
63GF Score
Get the complete analysis for DERM
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DERM has been successfully added to your 
